CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study
(Hinzugefügt: 24.03.2021 um 09:07 Uhr)
ADVANCE PURCHASE AGREEMENT (“APA”)1 for the development, production, advance purchase and supply of a COVID-19 vaccine for EU Member States
(Hinzugefügt: 23.03.2021 um 09:52 Uhr)